New preclinical study shows antibody therapy could offer treatment path for genetic form of ALS

New research published in the journal Neuron shows promise in opening a potential treatment pathway aimed at slowing the disease process and extending survival in patients with ALS, often called Lou Gehrig’s disease, an insidious neurological condition.

The mouse-model study by University of Florida neurogeneticists Laura Ranum, Ph.D., and Lien Nguyen, Ph.D.; Neurimmune; Biogen; and collaborators at Johns Hopkins University shows that targeting a specific mutant protein in the brain with a human-derived antibody can lower neuroinflammation, slow neurodegeneration and lengthen survival in the most common genetic form of amyotrophic lateral sclerosis, or ALS, and frontotemporal dementia, or FTD.

Read the UF Health news release.

Read the paper in the journal Neuron.

Drs. Laura Ranum and Lien Nguyen
Drs. Laura Ranum and Lien Nguyen
Drs. Laura Ranum and Lien Nguyen
Drs. Laura Ranum and Lien Nguyen
Drs. Laura Ranum and Lien Nguyen
Drs. Laura Ranum and Lien Nguyen